Products in
development
Our products aim to extend lifespan and quality of life by reducing incidence or severity of age-related diseases. We’re developing drugs in two categories:
Dexter
Age 13
Pipeline overview
Preclinical Studies
Pilot study
Companion dog clinical study
FDA conditional approval*
LOY-002
✓
✓
2025*
LOY-001
✓
2027*
LOY-003
✓
2027*
*FDA approval not guaranteed
LOY-002
*FDA approval
not guaranteed
not guaranteed
Extending lifespan by improving
metabolic health in
metabolic health in
Senior dogs
Extending lifespan by improving
metabolic health in
metabolic health in
Senior dogs
LOY-002
Anticipated timeline
2025*
Dosage form
Daily pill
*FDA approval not guaranteed
Chewy
Age 10
About
We’re developing LOY-002 to support healthy aging in senior dogs of nearly every size. The product is meant to target metabolic dysfunction, which may extend the number of healthy years your dog lives and support their quality of life as they age.
Sebastian
Age 11
Our STAY study for LOY-002 is actively enrolling new dogs
This study aims to gather data on the drug’s effectiveness in dogs within real-world clinical settings to support our application for FDA approval. This is the largest study of its kind ever conducted.
Learn about the STAY study
Abby
Age 13
LOY-001
LOY-003
*FDA approval
not guaranteed
not guaranteed
Longer, healthier lives for
Large and
giant dogs
giant dogs
Longer, healthier lives for
Large and
giant dogs
giant dogs
LOY-001
LOY-003
Anticipated timeline
2027*
Dosage form
Injectable or daily pill
*FDA approval not guaranteed
Akila
Age 7
About
Large and giant breed dogs can have as little as half the lifespan of smaller dogs. LOY-001 and LOY-003 target the biological mechanisms thought to cause this lifespan disparity.
Kirby
Age 5
Bode
Age 6
Two unique formulations
LOY-001
A veterinarian-administered long-acting product given to your dog a few times a year.
LOY-003
Designed as a daily pill for your dog, prescribed by your veterinarian.